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Abstract
Background: The prevalence of hyperuricemia varied in different populations and it appeared to be increasing in
the past decades. Recent studies suggest that hyperuricemia is an independent risk factor for cardiovascular
disease. However, there has not yet been a systematic analysis of the prevalence of hyperuricemia in China.
Methods: Epidemiological investigations on hyperuricemia in China published in journals were identified manually
and on-line by using CBMDISC, Chongqing VIP database and CNKI database. Those Reported in English journals
were identified using MEDLINE database. Selected studies had to describe an original study defined by strict
screening and diagnostic criteria. The fixed effects model or random effects model was employed according to
statistical test for homogeneity.
Results: Fifty-nine studies were selected, the statistical information of which was collected for systematic analysis.
The results showed that the pooled prevalence of hyperuricemia in male was 21.6% (95%CI: 18.9%-24.6%), but it
was only 8.6% (95%CI: 8.2%-10.2%) in female. It was found that thirty years was the risk point age in male and it
was fifty years in female.
Conclusions: The prevalence of hyperuricemia is different as the period of age and it increases after 30 years in
male and 50 in female. Interventions are necessary to change the risk factors before the key age which is 30 years
in male and 50 in female.
Background
Hyperuricemia (HU) is a result of multifactor interactions
including gender, age, genetic and environmental factors.
Classically, the following conditions are associated with
HU: alcoholism, obesity, hypertension, dyslipidemia,
hyperglycemia, diabetes mellitus, lithiasis, renal failure,
and medication use (diuretics, cyclosporine, low-dose
aspirin) [1]. In the past several decades, the prevalence var-
ied greatly and appeared to be increasing. There was lots
information that demonstrated the importance of serum
uric acid to the clinical prognosis, so the importance of
H Ui si n c r e a s i n g .I tr e p o r t e dt h a t1 8 . 8 %o ft h ep a t i e n t s
with HU developed into gout in a 5 year follow-up [2].
Independent association between HU and cardiovascular
disease has been found in many studies [3,4]. Hyperurice-
mia has been reported to be associated with several
components of metabolic syndrome (MetS) and authors
have postulated that increased concentrations of uric acid
may be another important component of the syndrome
[5].
With rapid economic development, possibility of
improved nutrition and promotion of successful heath and
medical care programs in China, life expectancy has been
prolonged and the elderly population has increased; thus
prevention and control of chronic diseases have become
more important than before. Hyperuricemia may induce
many complications, such as chronic gout, distortion of
joint and renal failure, which may increase medical care
costs. Therefore, it is important to study the hyperurice-
mia in China, in all developing countries, even in the
whole world.
Methods
Search strategy
Studies were identified from the following electronic data-
bases: CBMDISK, Chongqing VIP, CNKI and MEDLINE,
using the terms ‘hyperuricemia’, ‘HU’ and ‘prevalence’.N o
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study did not include epidemiological studies in the areas
of Hong Kong, Macao and Taiwan, because they are dif-
ferent from the Chinese mainland in the cultural activity
and socioeconomic status and hence the prevalence of
hyperuricemia and gout in those areas would be different
from the Chinese mainland.
Inclusion and exclusion criteria
In order to meet the analysis requirements and reduce
deviation, selected studies fulfilled the following criteria: (i)
case collection based on field survey; (ii) the study based
on population samples rather than volunteers; (iii) There
should be validated diagnostic criteria and accurate study
dates; (iv) If there were many articles based on the same
sample, only the one that reported the most detailed data
was included. It was confirmed that all articles had the
same diagnostic criteria. Studies were excluded if we could
not obtain information necessary for the computation of
prevalence in different sex and age from the articles or the
authors.
Quality of the studies
We accessed the quality of studies using the framework
suggested by the Cochrane Collaboration. For the inclu-
sion decision, quality assessment was carried out indepen-
dently by three reviewers. If two of them or three agreed,
the study can be included to the meta-analysis. The data
from all included studies were clearly tabulated, and devia-
tions were taken into account and identified during the
quality assessment stage.
Data analysis
We used a published systematic analysis technique to cal-
culate the pooled prevalence of hyperuricemia and gout
from all eligible studies. Summary of prevalence estimates
were obtained using fixed-effects or random-effects meta-
analysis which determined by I
2. Statistical heterogeneity
was assessed through I
2 statistic and its values of 25%, 50%
and 75% correspond to low, moderate and high heteroge-
neity. The date which was low heterogeneity was chose
the fixed-effects meta-analysis and others were chose ran-
dom-effects meta-analysis. Subgroup analysis including
sexes, ages and areas was also performed.
Results
Figure 1 summarized the process of identifying eligible
epidemiological studies. There were 59 [6-64] studies
left after the quality assessment. Table 1 showed the
characteristics of the studies, which covered 23 pro-
v i n c e si nt h er e v i e w .T h ep r e v a l e n c eo fH Ua n d9 5 % C I
in male and female were calculated separately for each
study, also the sample size and published years can be
found (Figure 2, Figure 3). The male population of
223,315 was investigated, and cases of 52,998 HU were
selected. It was 165,620 in female, and cases of 19,586
HU were selected. The pooled prevalence of hyperurice-
mia in male was 21.6% (95%CI: 18.9%-24.6%) and it was
only 8.6% (95%CI: 8.2%-10.2%) in female (Table 2), it
w a sa l s of o u n dt h a tt h ep r e v a l e n c ei nf e m a l ew a sl o w e r
than that in male in every age group. Table 2 also
showed the prevalence of hyperuricemia in different
gender and area. Heterogeneity of the analysis was
moderate. The prevalence ranged from 8.4% to 8.6% in
female, and it ranged from 19.6% to 26.8% in male.
Table 3 demonstrated the prevalence of hyperuricemia
in different age and area. It was found that thirty was
the risk point age in male and it was fifty in female. The
prevalence of female in northern and eastern China was
2.6% in ~30 age group, and it was high to 31.2% in wes-
tern China of male in 51-60 age group.
Discussion
The prevalence of hyperuricemia varies in different popu-
lations and areas. In Turkey [65], one study reported that
19% of the men and 5.8% of the women had hyperurice-
mia and the overall prevalence of hyperuricemia was
12.1% in the urban population. In Nepal [66], 3794 people
which were from Chitwan districts were investigated, and
the prevalence of hyperuricemia was 21.42%. In Seychelle
[67], the cross-sectional health examination survey based
on a population random sample which included 1011 sub-
jects aged 25 to 64 years showed that the prevalence of
hyperuricemia was 35.2% and 8.7% in men and women,
respectively. In Thailand [68], an across-sectional study of
Articles searched 
(n=216) 
Articles (n=199) 
Articles retrieved   
for more detailed       
evaluation (n=64) 
Excluded for duplication 
(n=5) 
Inclusion of 59 
articles in the review 
Excluded review 
articles (n=17) 
Excluded by diagnostic 
criteria and accurate 
study dates (n=135) 
Figure 1 Flow of information through the different phases of a
systematic review.
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Page 2 of 10Table 1 Characteristics of the studies
Study design
NO. First author
&y e a r
published
Age Location
(Western/Eastern)
(Northern/Southern)
Survey date Diagnostic criterion
(μmol/L)
(Male/Female)
Hyperuricemia no.(Male/Femal) Subjects no.
(Male/Female)
Prevalence
(%)(Male/
Female)
1[6] Miao et al.(2006) 20-80 Shandong(E) May 1995 - Aug 1996 >420/>350 435/225 2395/2608 18.16/8.63
2[7] Du et al.(1998) ≥15 Shanghai(E) Nov 1996 - Aug 1997 >417/>357 62/41 913/1124 6.79/3.65
3[8] Huang et al.(2006) ≥20 Jiangsu(E) Jan 2000-Apr 2006 ≥416.5/≥357 493/80 4950/1737 9.96/4.61
4[9] Li et al.(2002) 36-90 Henan(E) May 2000 >416/>357 210/24 737/142 28.49/16.90
5[10] He et al.(2003) 20-72 Sichuan(W) 2002 ≥420/≥360 552/75 1378/1108 40.06/6.77
6[11] Shao et al.(2003) ≥20 Jiangsu(E) Dec 2002-Mar 2003 ≥417/≥357 668/370 3790/3988 17.63/9.28
7[12] Wang et al.(2004) ≥40 Liaoning(E) ——— >416/>357 192 1000 19.2
8[13] Yu et al.(2005) 21-83 Guangdong(E) Jan 2003-Mar2004 ≥417/≥357 1655/697 7330/5994 22.59/11.63
9[14] Yu et al.(2005) 22-81 Guangdong(E) Jan 2003-June2004 ≥417/≥357 819/363 4106/3321 19.95/10.93
10[15] Zhang et al.(2006) 20-91 Shandong(E) Mar 2003-Dec 2004 >416.36/>356.88 424/225 2517/2855 16.85/7.88
11[16] Gu et al.(2006) 20-80 Guangdong(E) 2004 ≥417/≥357 4496/1304 16115/10506 27.90/12.41
12[17] Zhang et al.(2007) 28-88 Gansu(W) 2004 >440/>350 389/68 2372/360 16.40/18.89
13[18] Luan et al.(2007) 21-72 Tibet(W) Oct 2004 - Dec 2004 ≥440/≥360 454/25 537/159 84.54/15.72
14[19] Yao et al.(2007) ≥18 Shanghai(E) Oct 2004 - June 2005 ≥417/≥357 273/36 2965/2693 9.21/1.34
15[20] Li et al.(2007) 20-59 Ningxia(W) Jan 2004 - Dec 2005 >420/>350 410 9358 4.38
16[21] Zeng et al.(2005) 18-85 Guangxi(W) Jan 2004 - Aug 2005 ≥417/≥357 490/170 2800/2400 17.50/7.08
17[22] Mao et al.(2006) ≥20 Zhejiang(E) Apr 2004-Dec2004 ≥416/≥357 1214/160 7566/3450 16.05/4.64
18[23] Diao et al.(2005) 20-79 Guangdong(E) June 2004-June 2006 >357 0/853 0/7226 0/11.80
19[24] Li et al.(2009) 22-60 Qinghai(W) 2004-2007 >420/>350 134/2 819/275 16.36/0.73
20[25] Wu et al.(2007) 21-67 Zhejiang(E) 2005-2006 ≥416/≥357 250 1492 16.76
21[26] Sun et al.(2007) 20-70 Xinjiang(W) Jan2005 - Dec2005 >417/>357 104/18 379/315 27.44/5.71
22[27] Xie et al.(2008) 18-92 Chongqing(W) June2005 - Dec2005 >380/>300 1244/483 5962/3566 20.87/13.54
23[28] Fang et al.(2006) 20-90 Beijing(E) Sept2005 - Dec2005 ≥416.4/≥356.9 163/46 1181/762 13.80/6.04
24[29] Cao et al.(2009) >20 Zhejiang(E) 2005-2007 ≥417/≥357 2516/651 9615/7639 26.17/8.52
25[30] Wu et al.(2007) 19-87 Guangdong(E) ———— ≥417/≥357 258/93 911/571 28.32/16.29
26[31] Li et al.(2008) >60 Guangdong(E) 2006 >420 156/45 519/425 30.06/10.59
27[32] Jin et al.(2007) 26-57 Jilin(E) ———— ≥408/≥357 97/2 350/32 27.71/6.25
28[33] Chen et al.(2009) >20 Yunnan(W) Jan 2006 - Dec 2006 >420/>350 580/343 3593/3912 16.14/8.77
29[34] Wu et al.(2008) >16 Guangdong(E) Nov2006-Feb2007 ≥417/≥357 369/217 1366/1422 27.01/15.26
30[35] Zeng et al.(2008) 22-79 Hunan(W) Dec 2006 - Jan 2007 ≥417/≥357 405/103 1346/994 30.09/10.36
31[36] Wanget al.(2008) 20-78 Heilongjiang(E) Feb2006 - Jan 2008 ≥417/≥357 502/125 2390/1824 21.00/6.85
32[37] Tian et al.(2008) ≥35 Shanghai(E) Mar2006 - Sept2006 >420/>350 425/451 1887/2943 22.52/15.32
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0Table 1 Characteristics of the studies (Continued)
33[38] Wei et al.(2008) 20-70 Hebei(E) May2006 - Dec 2006 ≥420/≥350 197/86 1146/859 17.19/10.01
34[39] Deng et al.(2007) 41-93 Liaoning(E) Sept2006 - Nov2006 >416/>339 250/45 936/218 26.71/20.64
35[40] Wen et al.(2007) 35-64 Shandong(E) Sept2006 - Dec 2006 ≥417/≥357 126/44 1979/2062 6.37/2.13
36[41] Zeng et al.(2009) ≥20 Zhejiang(E) 2006-2007 ≥417/≥357 1797/520 6591/5649 27.26/9.21
37[42] Zhong et al.(2008) 22-92 Hunan(W) 2007 ≥420/≥360 178/34 919/497 19.37/6.84
38[43] Zheng et al.(2008) 20-92 Guangdong(E) 2007 ≥420/≥350 4355/1239 18589/10526 23.43/11.77
39[44] Huang et al.(2009) 60-90 Shanghai(E) 2007 ≥420/≥360 288/139 1423/1466 20.24/9.48
40[45] Chen et al.(2008) 20-90 Chongqing(W) 2007 ≥417/≥357 4772/951 8352/7471 57.14/12.73
41[46] Liu et al.(2008) ≥60 Zhejiang(E) Oct2007 - Feb2008 >420 445/213 1964/3321 22.66/6.41
42[47] Jia et al.(2009) 20-101 Hebei(E) Jan2007-Nov2007 >401.52/>249.20 802/180 6703/1832 11.96/9.83
43[48] Han et al.(2008) 19-87 Beijing(E) Jan2007-Nov2007 ≥417/≥357 139/61 540/580 25.74/10.52
44[49] Yuan et al.(2009) 20-85 Zhejiang(E) Nov 2007 - Dec2007 ≥417/≥357 1607/243 4958/2562 32.41/9.48
45[50] Gao et al.(2008) 18-94 Anhui(W) Jan2007 - Dec 2007 >429/>340 2883/609 26066/13758 11.06/4.43
46[51] Wu et al.(2009) 23-59 Guangxi(W) Jan2007 - May2009 >420/>360 111/20 825/407 13.45/4.91
47[52] Yang et al.(2009) 24-67 Tibet (W) Jan2007 - May2009 ≥417/≥357 646/136 1874/993 34.53/13.70
48[53] Wang et al.(2008) 45-96 Zhejiang(E) Jan2007 - June 2007 ≥420/≥360 690/335 1796/3341 38.42/10.03
49[54] Quan et al.(2008) 32-77 Jilin(E) Mar 2007 ≥420/≥350 42/29 468/686 8.97/4.23
50[55] Liu et al.(2008) 27-82 Liaoning(E) Apr 2007 - Apr 2008 >420/>350 220/139 1144/923 19.23/15.06
51[56] Wang et al.(2008) >16 Zhejiang(E) May 2007 >420/>360 126/31 518/920 24.32/3.37
52[57] Ding et al.(2008) 21-61 Jiangsu(E) May 2007 >420/>340 11/7 118/239 9.32/2.93
53[58] Zhang et al.(2009) 20-90 Guangdong(E) Sept2007-Aug2008 ≥417/≥357 1147/248 6137/2679 18.69/9.26
54[59] Huang et al.(2009) 20-80 Fujian (E) Jan2008 - Sept2008 >416/>339 9458/6046 24140/20034 39.18/30.18
55[60] Li et al.(2009) 30-69 Guangdong(E) Mar2008 - Oct2008 ≥428/≥340 2043/629 9189/7128 22.23/8.82
56[61] Wang et al.(2009) 60-98 Beijing(E) July2008 - June2009 ≥417 416/208 2295/2266 18.13/9.18
57[62] Wang et al.(2009) 19-65 Zhejiang(E) Aug2008 ≥417/≥357 191/76 599/702 31.89/10.83
58[63] Cao et al.(2010) >20 Hainan(E) Sept 2008-Nov 2008 ≥417/≥350 181/23 663/150 27.30/15.33
59[64] Jiang et al.(2010) 20-93 Beijing(E) Mar2009 - Sept2009 ≥417/≥357 290/96 2585/1722 11.22/5.57
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01381 patients who firstly participated in annual health
examinations during the period of July 1999 through
February 2000 reported that the prevalence of hyperurice-
mia was 10.6%, but it was 18.4% and 7.8% in men and
women, respectively. In Java [69], the prevalence of hyper-
uricemia was investigated by a survey of a total population
of 4683 rural adults and the result was 24.3%. In United
States [70], the prevalence rate of asymptomatic
Figure 2 Forest plot of the studies for the male.
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Page 5 of 10hyperuricemia in the general population was estimated at
2-13%. The prevalence of gout and/or hyperuricemia
increased about 2 cases per 1000 enrollees over 10 year
(1990-1999) in the overall population. In Japan [71], a
total of 9,914 individuals (6,163 men and 3,751 women
aged from 18 to 89 years) who were screened at Okinawa
General Health Maintenance Association was screened.
The result showed that the prevalence of hyperuricemia
 
Figure 3 Forest plot of the studies for the female.
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Page 6 of 10was 25.8% and it was 34.5%, 11.6% in men and women
respectively. In New Zealand [72], hyperuricemia was
more common in Maori men (27.1%) than in European
men (9.4%) and in Maori women (26.6%) than in Eur-
opean women (10.5%). In Saudi Arabia [73], the preva-
lence of hyperuricemia was only 8.84%. In Taiwan island
of China [74], the prevalence of hyperuricemia was high to
49.4% in Ayatals, but it was only 27.4% in non-aborigines.
From the analysis, it was found that age and sex
affected the serum uric acid levels and the prevalence of
hyperuricemia:
The factor of age
It was found that the prevalence of hyperuricemia
increased with the age in male and female. The prevalence
was higher in male who were after 30 years old than that
younger. But the point age was 50 in female. The physiolo-
gic and economic reasons may explain this difference.
After 30 years old, the male would have a stable family
and career. In female, the influence of sexual hormones
may explain the point age. Young children of both sexes
have equally low urate levels, so the prevalence is low. The
study of Katrine demonstrated that the 45-64 age group
was higher prevalence compared with the 18-44 age group
[75]. Vitool’s study showed that the prevalence were 4.3%
and 1.3% in men and women, who were younger than 18
years, but it increased to 17.4% and 15.4% in the men and
women from 30 to 39 [68]. A study about elderly people
in Taiwan reported that Men at age 65 to 69 had the high-
est proportion of hyperuricemia which was 69.8%, but
Table 2 The prevalence of hyperuricemia in different gender and area
China Gender Case/Total
(No. of Studies)
Pooled
Estimate (%)
95%CI(%) Heterogeneity
I2 P-value
Northern
China
Male 8923/59413(n = 21) 19.6 15.7-24.1 49.8% 0.00
Female 2393/35231(n = 21) 8.4 6.6-10.5 49.2% 0.00
Southern
China
Male 44075/163902(n = 34) 22.7 19.6-26.1 49.9% 0.00
Female 17289/132111(n = 35) 8.8 7.1-10.8 49.9% 0.00
Eastern
China
Male 40056/166093(n = 41) 20.1 17.8-22.6 49.8% 0.00
Female 16645/131127(n = 42) 8.6 7.0-10.6 49.8% 0.00
Western
China
Male 12942/57222(n = 14) 26.8 17.3-39.0 50.0% 0.00
Female 3037/36215(n = 14) 8.5 6.5-11.2 49.5% 0.00
Total Male 52998/223315 (n = 55) 21.6 18.9-24.6 49.9% 0.00
Female 19586/165620 (n = 55) 8.6 7.2-10.2 49.8% 0.00
Table 3 The prevalence of hyperuricemia in different age
China Gender Age
~30 31-40 41-50 51-60 61-70 >70
Northern
China
Male 11.6(8.8-15.1) 16.4(12.7-20.9) 20.9(16.0-26.7) 21.0(14.2-29.9) 17.3(14.4-20.6) 17.9(13.8-23.0)
Female 2.6(1.5-4.5) 3.8(2.4-5.9) 7.6(5.5-10.2) 14.3(9.1-21.7) 13.2(9.5-18.2) 20.2(14.4-27.6)
Southern
China
Male 16.8(11.4-24.2) 24.4(16.3-34.9) 24.9(19.6-31.2) 23.5(19.5-27.9) 22.6(19.7-25.7) 27.2(22.5-32.4)
Female 3.1(1.8-5.4) 3.6(1.7-7.6) 6.2(3.5-10.7) 15.1(11.1-20.2) 19.8(13.6-27.8) 25.3(17.6-35.0)
Eastern
China
Male 13.1(9.5-17.7) 17.4(13.4-22.2) 20.4(16.7-24.7) 19.6(16.4-23.2) 19.9(17.3-22.8) 24.2(21.0-27.7)
Female 2.6(1.5-4.6) 3.5(2.6-6.7) 6.8(4.2-10.6) 12.4(9.4-16.2) 15.3(10.7-21.6) 22.4(16.2-30.0)
Western
China
Male 17.5(6.3-40.1) 29.9(8.3-67.0) 31.0(18.8-46.4) 31.2(18.9-46.9) 25.6(18.7-27.0) 24.6(10.3-48.1)
Female 4.7(3.4-6.5) 4.2(2.6-6.7) 7.5(5.2-10.6) 22.9(11.7-39.8) 24.6(16.1-35.6) 31.1(24.5-38.6)
Total Male 14.2(10.4-19.2) 20.1(15.3-26.0) 22.9(18.9-27.5) 22.3(18.8-26.2) 23.3(18.0-24.9) 24.1(20.6-28.0)
Female 2.8(1.8-4.5) 3.5(2.0-6.2) 6.6(4.5-9.7) 14.7(11.5-18.6) 16.8(12.5-22.4) 23.4(17.7-30.4)
Note: The I
2 of all studies in the table ranged from 45% to 50%.
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Page 7 of 10woman at age more than 80 had the higher prevalence
which was 50% [76].
The factor of sex
From the previous studies, it was found that serum uric
acid levels were higher in men than in women, but it
tended to be consistent between man and woman after
the age of 50 [77,78]. The study of Gordon explained it
that serum uric acid level increased after the menopause
in females which attributed to the influence of sexual hor-
mones [79]. The results of the study showed that male
subjects had a higher prevalence of hyperuricemia than
women, which was in line with findings of many studies
from different countries [65-74].
Health Education and life customs
From the result of meta-analysis, it was found that the pre-
valence in different age of southern China was higher than
that in northern China and the prevalence in western was
higher than that in eastern, especially in male. The reason
for that may be different life customs. In southern China,
the mainly food is rice and it is sweat in northern China.
In the eastern China, the health service is better than that
in western China. More health educations were carried
out and the people had more health knowledge in eastern
China, which may affect the prevalence of hyperuricemia.
The reasons for the difference in prevalence need further
research.
Conclusions
In conclusion, aging trend is more and more serious in
China, even all the word, and the prevalence of hyperuri-
cemia is higher in elderly. It was found that urate levels
correlate with many recognized cardiovascular risk factors,
including hypertension, diabetes mellitus, hypertriglyceri-
demia, obesity and insulin resistance. Multiple Risk Factor
Intervention Trial (MRFIT) database showed that hyperur-
icemia was an independent risk factor for acute myocar-
dial infarction [75]. The Italian Progetto Ipertensione
Umbria Monitoraggio Ambulatoriale (PIUMA) study
showed that serum urate levels in the highest quartile
were associated with increased risk of all cardiovascular
events (relative risk [RR] = 1.73) and fatal cardiovascular
events (RR = 1.96) compared with urate levels in the sec-
ond quartile[76]. So it is important to control the preva-
lence in elderly. Interventions are necessary to change the
risk factors before the key age which is 30 years in male
and 50 in female. At the same time, intervention to high
risk group is urgent.
In China, most of the studies concerned the eastern,
especially in the urban areas, but it is necessary to study
the western of China and rural areas. The cohort study
with larger sample is necessary. This article only provides
the narrowing window of hyperuricemia in China.
Author details
1Jinan Institute of Cardiovascular Disease, The Fourth People’s Hospital of
Jinan, Shifan Road, Jinan, 250031, China.
2Department of Public Health, The
Second Affiliated Hospital of Soochow University, Sanxiang Road, Suzhou,
215000, China.
Authors’ contributions
LB and WT gave the biggest contributions to the passage; JRY gave the
point about the passage; ZHHN, YWW, YHP, LCX, YJ helped to analysis and
interpret data; NHW helped to revise the language problems. All authors
read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 March 2011 Accepted: 27 October 2011
Published: 27 October 2011
References
1. Vazquez-Mellado J, Alvarez Hernandez E, Burgos-Vargas R: Primary
prevention in rheumatology: the importance of hyperuricemia. Best Pract
Res Clin Rheumatol 2004, 18(2):111-124.
2. Lin KC, Lin HY, Chou P: The interaction between uric acid level and other
risk factors on the development of gout among asymptomatic
hyperuricemic men in a prospective study. Journal of Rheumatology 2000,
27:1501-1505.
3. Alderman MH, Cohe H, Madhavan S, Kivlighn S: Serum uric acid and
cardiovascular events in successfully treated hypertensive patients.
Hypertension 1999, 34:144-150.
4. Bos MJ, Koudstaal PJ, Hofman A, Witteman JC, Breteler MM: Uric acid is a
risk factor for myocardial infarction and stroke: the Rotterdam Study.
Stroke 2006, 37:1503-1507.
5. Bonora E, Targher G, Zenere MB, Saggiani F, Cacciatori V, Tosi F, et al:
Relationship of uric acid concentration to cardiovascular risk factors in
young men. Int J Obes Relat Metab Disord 1996, 20:975-980.
6. Miao Zh-M, Zhao Sh-H, Wang YG, Li Ch-G, Wang Zh-Ch, Chen Y, et al:
Epidemiological survey of hyperuricemia and gout in coastal areas of
Shandong Probince. Chin J Endocrinol Metab 2006, 22(5):421-425.
7. Du S, Chen Sh-L, Wang Y, Xu LQ: The epidemiological of hyperuricemia
and gout in a community population of Huangpu district in Shanghai.
Chin J Rheumatol 1998, 2(2):75-78.
8. Huang RG, Song XH: The relationship between the serum uric acid and
hypertension. Chin J Convalescent Med 2006, 15(6):404-406.
9. Li H, Zhang MX, Xiao J: The prevalence of hyperuricemia, people from
the government office in Henan. Journal of Zhengzhou University(Medical
Sciences) 2002, 37(1):87-88.
10. He XQ, Hao R, Zheng YP: The analysis of uric acid levels about 2486
people. Chengdu Medical Journal 2003, 29(4):203-204.
11. Shao JH, Mo BQ, Yu RB, Li Zh, Liu H, Xu Y-CH: Epidemiological study on
hyperuricemia and gout in community of Nanjing. Chin J Dis Control Prev
2003, 7(4):305-308.
12. Wang Y: The analysis of uric acid levels about 1000 people. Chinese
Journal of Rural Doctor 2004, 11(6):18.
13. Yu JW, Lu JB, Zhang XJ, Yang YB, Liu BL, Yu SH-Y: The Analysis of Blood
Uric Acid Level and the Indications Associate with Hyperuricemiain
13324 Foshan’ s Inhabitants. Chinese Journal of Integrated Traditional and
Western Nephrology 2005, 6(7):401-403.
14. Yu JW, Lu JB, Zhang XJ, Yang YB, Liu BL: Study on hyperuricemia with
hyperlipaemia, high blood sugar and hypertension in 1320 elderly
people. Chin J Epidemiol 2005, 26(6):455-457.
15. Zhang X-SH, Yu WG, Yu LX, Zhang LY, Yu Y: An epidemiologic study on
hyperuricaemia and gout in residents of coastal areas of Hai yang City
in Shan dong. Chin J Gen Pract 2006, 5(4):216-219.
16. Gu P: The incidence of hyperuricemia in 26621 health check up persons
in Guangzhou City and analysis of associated diseases. China Tropical
Medicine 2006, 6(6):1082-1084.
17. Zhang WX, Chen H, Yue ZH-F: The investation of hyperuricemia in Lan
zhou, people from government office. Vocation Education 2007,
25(9):130-131.
18. Luan M, Wang SH-B, Chen Y, Guan ZH-F: The incidence of hyperuricemia
in 696 who from Tibet. Chin J Prev Med 2007, 41(2):143-144.
B et al. BMC Public Health 2011, 11:832
http://www.biomedcentral.com/1471-2458/11/832
Page 8 of 1019. Yao ZL, Jiang SH-J, Liu H, Wan XQ, Ding ZH-G: Epidemiological study on
hyperuricemia and gout in the coastal area of Qingdao city. Chin J
Rheumatol 2007, 11(11):672-675.
20. Li J, Wang TR, Wu XY: The analysis of the result about young and
Middle-aged physical examination. Ningxia Med J 2007, 29(4):369-370.
21. Zeng XG: The epidemiological of hyperuricemia and gout about railway
workers in Nanning. Heilongjiang Medical Journal 2005, 29(11):876-877.
22. Mao Y-SH, Zhou LN, Ye HY, Huang T, Chen CH-X, Du J, et al:
Epidemiological survey on prevalence of hyperuricemia and gout in
staff of a petrchemical corporation in Ningbo. Chin J Endocrinol Metab
2006, 22(4):338-341.
23. Diao WX, Yu JW, Zhu J, Zhang XJ, Yu SH-Y, Liu BL: The survey on uric acid
levels in female from Foshan, Guangdong. New Medicine 2007,
38(10):667-668.
24. Li YM: The prevalence of hyperuricemia and dietary intervention in
Xi’ning. Qinghai Medical Journal 2009, 39(8):80-81.
25. Wu XH, Wu SH-ZH, Xu HL: The analysis of metabolic syndrome in physical
examination from 1492 people. Zhejiang Prev Med 2007, 19(8):19-20.
26. Sun YP, Yao H, Aimulajing M, Cai ZH-H, Nuermaimait K, Gulinisha K, et al:
The analysis of uric acid level and the prevalence of hyperuricmia in
Uygur ethnic population. Journal of Xinjiang Medical University 2007,
30(5):458-460.
27. Xie WB, Wang YX, Zhang MJ, Xie YH, Song L, Lu Y: Study on the
relationship between hyperuricemia and lipid metabosism, hyperten
abnormality, and barc index by 9528 examples of their health
examination in Chongqing. Journal of Chongqing Medical University 2008,
33(7):843-846.
28. Fang WG, Huang XM, Wang Y, Zhu WG, Bie ZH-X, Chen JL, et al: A Cross-
sectional study of hyperuricemia in state-employees in Beijing:
prevalence and risk factors. Natl Med J China 2006, 86(25):1764-1768.
29. Cao LJ, Hong XP: Analysis of serum uric acid level in a population of
Zhenhai district. Laboratory Medicine 2009, 24(11):804-807.
30. Wu WR, Guo JM, Yang W, Luo HB: The prevalence of hyperuricemia and
gout among 1482 subjects for health check in Guangzhou. Hainai
Medicine 2007, 18(9):110-112.
31. Li H, Zhang J: The relationship between hyperuricemia and risk factors in
People aged intellectuals. Guangdong Medical Journal 2008,
29(10):1735-1736.
32. Jin X, Jiang CH-SH, Jin CH-H: Analysis on the prevalence of
hyperuricaemia among the policeman in Yanbian. Modern Preventive
Medicine 2007, 34(21):4156-4157.
33. Chen XY, Yang HD, Yang JY: The prevalence of hyperuricemia and gout
about Urban residents in Dali, Yunnan. China Prac Med 2009,
4(10):257-259.
34. Wu WR, Gui JR, Yang W, Zhong ZH-G, Liu YH, Luo HB: Epidemiology of
Hyperuricemia and Gout in a Community in Guangzhou. Chinese Journal
of General Practice 2008, 6(7):728-729.
35. Zeng Y-CH, Huang X, Zhou GY, Hu MY: The prevalence of hyperuricemia
and related factors in Changsha. Journal of Hygiene Research 2008,
37(6):679-681.
36. Wang JM, Jin JY, Li CH-J: The survy on hyperuricemia in Jiamusi. China
Modern Doctor 2008, 46(23):77-78.
37. Tian XC, Jiang Z-CH, Bao G-CH, Gao WG, Nan HR, Wang SH-J, et al: Analysis
on prevalence and influence factors of hyperuricemia among residents
in Qingdao. Chin J Pubic Health 2008, 24(3):360-362.
38. Wei GX, Gao CH-H, Si RJ, Jiang PF, Liu W-ZHL: The prevalence of
hyperuricemia and related factors in the town of Xinglong, Chengde.
Chin J Misdiagn 2008, 18(16):4022-4023.
39. Deng SH-SH, Zhang Q, Wang XF, Cao CP, Sun G, Meng J, et al: The current
conditions of serum uric concentrations in parts of the middle-aged and
elderly population of Shenyang. Journal of China Medical University 2007,
36(6):712-714.
40. Wen XY, Lu FH, Yang JM, Liu ZH-D, Zhou XH, Jin SH-K, et al: Analysis on
hyperuricemia and its influential factors in population. Chin J Pubic
Health 2007, 23(12):1520-1522.
41. Cao LJ, Li QW: The analysis of Metabolic indicators about physical
examination from one government office. Shanghai Journal of Preventive
Medicine 2009, 21(4):171-172.
42. Niu X, He QN, Lin YP, Zhou G, Zeng WH: The analysis about
hyperuricemia and related diseases in teachers groups. Chin J Pubic
Health 2008, 24(1):118-119.
43. Zheng ML, Lai YH, He XN, Tan FW: Correlation of detection of
hyperuricemia with hypertension in healthy population in Guangzhou
City. China Tropical Medicine 2008, 8(3):512-514.
44. Huang SH-X: The analysis of hyperuricemia and related diseases in
elderly people. PJCCPVD 2009, 17(8):675-676.
45. Chen YQ: The prevalence of hyperuricemia and related factors which is
from urban population in Chongqing. Journal of Third Military Medical
University 2008, 30(11):1013-1014.
46. Liu CL, Wang WW, Chen J, Zhou W: The analysis of glucose, liver and
renal function about elderly people in Wenzhou. Experimental &Lab Med
2008, 26(4):397-399.
47. Jia YH, Cui LF, Yang WH, Shu R, Song H-CH, Han YX, et al: Epidemiological
survey on morbidity of hyperuricemia and gout in Tangshan Mining
district. Chinese Journal of Coal Industry Medicine 2009, 12(12):1933-1935.
48. Han XH, Yao XY, Fang X-SH: The prevalence of hyperuricemia and
abnormal of lipid and glucose in Medical examination population.
Shanxi Med J 2008, 37(5):438-439.
49. Yuan HP, Hu XF, Liu XG, Bao ZH-J: Analysis on detection of hyperuricemia
for cadres in island areas and strategies. Nursing and Rehabilitation 2009,
8(3):188-189.
50. Gao CH-J, Jiang YG, Tang ZH-L: The epidemical analysis of hyperuricemia
to 39824 people in Anhui. The Journal of Practical Medicine 2008,
24(20):3589-3590.
51. Wu J-EN, Chen F: The survy of the prevalence of hyperuricemia in 1230
government officials. China Prac Med 2009, 14(32):206.
52. Yang C, Liu G-ZH, Liu YX, Feng GJ: Hyperuricemia in Tibetans Undergoing
Health Examination in Linzhi District in Tiebet. Military Medical Journal of
South China 2009, 23(6):10-12.
53. Wang SP, Zhang WJ, Hong JX: A Study of Morbidity and Cor r elative
Factors of Hyperuricemia Among Middle and old Aged People. Chinese
Primaty Health Care 2008, 22(1):71-73.
54. Jin ZH-Y, Han CH-J, Yu XL: The survy of uric acid levels in Han and
Korean. Chinese Journal of Clinical Laborat ory Science 2008, 26(5):386-387.
55. Liu MK, Yu Y-ZH, Dong F-ZH, Yu JL: Examination and Analysis of Blood
Uric Acid Level in 2067 Inhabitants of Dalian. Practical Preventive Medicine
2008, 15(5):1602-1604.
56. Wang LJ, Fu HP, Sun Y, Cai WH: A Survey of Metabolic Syndrome and its
Related Diseases in Fishing Village in Island. Zhejiang Prev Med 2008,
20(10):8-10.
57. Ding YH: The analysis of hyperuricemia in Hospital staff. Jiangxi Medical
Journal 2008, 43(3):261.
58. Zhang Y, Feng L, Huang LW: Study on relationship between epidemic
characteristics and Metabolic syndrome. 2009, 9(7):10-13.
59. Huang HB, Jin HW, Chen ZH-SH: The analysis of hyperuricemia about
medical examination population in Xiamen. Henan J Prev Med 2009,
20(5):345-347.
60. Li ZH: Investigation of the level of blood uric acid, blood lipid and
hypertension in dongguan. Modern Hospital 2009, 19(4):154-155.
61. Wang J, Gu X-EN, Jiang Y, Yin ZH-N: Analysis of the detection of
hyperuricemia in eldly people. Chinese Journal for Clinicians 2009, 37(3):47-48.
62. Liu QF, Guo LJ, Chen SH-P: The analysis of healthy conditions about rural
teachers in Liandu, Lijiang. Chinese Primary Healthy Care 2009,
23(11):114-115.
63. Cao YJ, Liu Y, Li T, Yan BS, Wang ZH-ZH, Yang XL: Investigation of the
increasing of policemen in blood uric acid and Triglyceride in Haikou.
Hainan Medical Journal 2010, 21(1):120-121.
64. Jiang Y: The analysis of serum uric acid levels in healthy people in
Beijing. Chinese Journal of Coal Industry Medicine 2010, 13(2):271.
65. Ismail S, Servet A, Betul P, Ali RS, Oguz G, Merih B, et al: Hyperuricemia and
its related factors in an urban population, Izmir, Turkey. Rheumatol Int
2009, 29:869-874.
66. Kumar S, Singh AR, Takhelmayum R, Shrestha P, Sinha JN, et al: Prevalence
of hyperuricemia in Chitwan District of Nepal. Journal of college of
Medical Sciences-Nepal 2010, 6(2):18-23.
67. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F, et al:
Prevalence of hyperuricemia and relation of serum uric acid with
cardiovascular risk factors in a developing country. BMC Public Health
2004, 4:9.
68. Vitoon J, Rungroj K, Thananya B, Kamol U, Suthipo U: Prevalence of
Hyperuricemia in Thai Patients with Acute Coronary Syndrome. Thai
Heart J 2008, 21:86-92.
B et al. BMC Public Health 2011, 11:832
http://www.biomedcentral.com/1471-2458/11/832
Page 9 of 1069. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD: The epidemiology of
gout and hyperuricemia in a rural population of Java. J Rheumatol 1992,
19:1595-1599.
70. Edward W, Campion MD, Robert J, Glynn SD, Lorraine O, Delabry MA:
Asymptomatic hyperuricemia. Risks and consequences in the normative
aging study The American Journal of Medicine 1987, 82(3):421-426.
71. Kazufumi N, Kunitoshi I, Taku I, Takashi T, Yosiharu I, Shuichi T:
Hyperuricemia and Cardiovascular Risk Factor Clustering in a Screened
Cohort in Okinawa, Japan. Hypertens Res 2004, 27:227-233.
72. Patrick K, Shelley AS, Benjamin C, Robertson MC: Gout is on the increase in
NewZealand. Annals of the Rheumatic Diseases 1997, 56:22-26.
73. Abdurhman SA-A: Hyperuricemia in Saudi Arabia Rheumatol Int. 2001,
20:61-64.
74. Huang CL, Chen KT: An epidemiological survey of hyperuricemia among
the Atayals of Nanau Township, Iian county. Epidemiology Bulletin 1996,
12(5):71-81.
75. Krishnan E, Baker JF, Furst DE, Schumacher HR Jr: Gout and the risk of
acute myocardial infarction. Arthritis Rheum 2006, 54:2688-2696.
76. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P:
Relation between serum uric acid and risk of cardiovascular disease in
essential hypertension. The PIUMA study Hypertension 2000, 36:1072-1078.
77. Freedman DS, Williamson DF, Gunter EW, Byers T: Relation of serum uric
acid to mortality and ischemic heart disease. The NHANES I
epidemiologic follow-up study. Am J Epidemiol 1995, 141:637-644.
78. Culleton BF, Larson MG, Kannel WB, Levy D: Serum uric acid and risk for
cardiovascular disease and death: The Framingham Heart Study. Ann
Intern Med 1999, 131:7-13.
79. Gordon T, Kannel WB: Drinking and its relation to smoking, blood
pressure, blood lipids, and uric acid. The Framingham Study Arch Int Med
1983, 143:1366-1374.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/11/832/prepub
doi:10.1186/1471-2458-11-832
Cite this article as: B et al.: The prevalence of hyperuricemia in China:
a meta-analysis. BMC Public Health 2011 11:832.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
B et al. BMC Public Health 2011, 11:832
http://www.biomedcentral.com/1471-2458/11/832
Page 10 of 10